Quantum BioPharma has received two key final reports related to its potential breakthrough drug for Multiple Sclerosis: the 90-day oral toxicity study report and the toxicokinetic study report for Lucid-21-302. These studies were commissioned to provide key data to support an Investigational New Drug application with the US FDA for a phase-2 clinical trial in Multiple Sclerosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Strengthens MS Program with New Clinical Advisor
- Quantum BioPharma appoints Jack Antel as clinical development advisor
- Quantum BioPharma Announces Shareholder Meeting Results
- Quantum BioPharma announces Annual General, Special Meeting results
- Quantum BioPharma’s Licensee Unbuzzd Wellness to Host Investor Webinar on Innovative Hangover Solution